CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04084171
NCT04084171N/ACompleted
CompareCT.gov

Safety of the Tandem t:Slim X2 With Control-IQ Automated Insulin Delivery System in Preschoolers, Age 2-6 Years Old

University of Virginia·interventional·Posted Sep 10, 2019·Updated Mar 22, 2023

In Brief

A clinical study evaluating Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 for Type 1 Diabetes. Completed, enrolled 12 participants across 3 sites.

Detailed Summary

A single-arm, multi-center, clinical study to assess the safety profile of the Tandem t:slim X2 with Control-IQ system in children with T1D aged 2-6 years old under free living condition

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsDexCom, Inc., Tandem Diabetes Care, Inc.

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedSep 10, 2019
Enrollment StartSep 26, 2019
Primary CompletionOct 23, 2019
TodayJul 2, 2026
Enrollment to primary: 27 daysPosted 6.8 years ago

Interventions

Tandem t:slim X2 with Control-IQ Technology + Dexcom G6device

Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].